Literature DB >> 16818683

Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.

Robert L Ferris1, Theresa L Whiteside, Soldano Ferrone.   

Abstract

Recent revival of interest in the role of immune surveillance in the pathogenesis and control of malignant diseases has focused attention on escape mechanisms used by tumor cells to evade immune recognition. Defects in the host's tumor antigen-specific immune responses and abnormalities in tumor cell expression of HLA class I molecules and tumor antigen are known to contribute to tumor progression. However, the mechanism(s) responsible for the lack of tumor cell recognition by functional HLA class I antigen-restricted, tumor antigen-specific CTLs despite expression of the restricting HLA class I allele and targeted tumor antigen by tumor cells remain(s) unexplained. In squamous cell carcinomas of the head and neck (SCCHN), this type of tumor escape is a rule rather than the exception. Here, we discuss evidence pointing to functional defects in the antigen-processing machinery as one mechanism underlying resistance of SCCHN cells to recognition and lysis by HLA class I antigen-restricted, tumor antigen-specific CTL. In addition, based on the restoration by IFN-gamma of SCCHN cell sensitivity to recognition by these CTL, we suggest strategies that may improve the clinical course of the disease by enhancing susceptibility of malignant cells to immune recognition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818683     DOI: 10.1158/1078-0432.CCR-05-2750

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  84 in total

Review 1.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 2.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

3.  Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  Rebecca C Hoesli; Jeffrey S Moyer
Journal:  Curr Oral Health Rep       Date:  2016-03-12

4.  Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Authors:  Sonja Ludwig; Theofanis Floros; Marie-Nicole Theodoraki; Chang-Sook Hong; Edwin K Jackson; Stephan Lang; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

5.  Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Authors:  Sara D Johnson; Corinne Levingston; M Rita I Young
Journal:  Anticancer Res       Date:  2016-07       Impact factor: 2.480

Review 6.  Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.

Authors:  Albert B DeLeo; Theresa L Whiteside
Journal:  Expert Rev Vaccines       Date:  2008-09       Impact factor: 5.217

7.  Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.

Authors:  Alan A Z Alexander; Amudhan Maniar; Jean-Saville Cummings; Andrew M Hebbeler; Dan H Schulze; Brian R Gastman; C David Pauza; Scott E Strome; Andrei I Chapoval
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

8.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.

Authors:  Hyun-Bae Jie; Yu Lei; Jing Li; Neil Gildener-Leapman; Sumita Trivedi; Tony Green; Lawrence P Kane; Robert L Ferris
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

10.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.